PACB stock sentiment todayPacific Biosciences of California, Inc.
Sentiment verdict
Gossip first, financials second — COLD at 85% confidence.
Last updated · cached analysis, refreshes periodically
PACB
Pacific Biosciences of California, Inc.PACB is trapped in a liquidity crunch characterized by slowing instrument placements, heavy cash burn, and a loss of investor confidence in its long-read sequencing monopoly.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for PACB. Not financial advice.
Price · last 12 months
Gossip
The prevailing narrative is one of 'broken promises.' After a period of hype around the Revio system, the market is reacting to significant revenue misses and lowered full-year guidance. Chatter centers on the 'funding gap' and the fear of dilutive capital raises or a potential delisting risk if the share price doesn't stabilize above $1.00.
- ·Lowered 2024 revenue guidance
- ·Slowing capital equipment spending in biotech
- ·Rumors of further workforce reductions
- ·Competitive pressure from cheaper short-read alternatives
Financial
PACB is currently burning through cash at an unsustainable rate relative to its market cap. While they have a significant cash runway into 2025/2026, the lack of a clear path to profitability (GAAP) and declining gross margins due to manufacturing underutilization are major red flags.
- ·Negative 50%+ Operating Margin
- ·Significant revenue miss in Q1 2024
- ·Price-to-Sales ratio collapsed from historical highs
- ·High debt-to-equity following convertible note issuances
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $30K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Continued contraction in R&D spending by customers
- ·Intense competition from Oxford Nanopore in long-read
- ·Dilution risk from potential future equity offerings
- ·Execution risk on the new Onso short-read platform
Peer temperature
How direct competitors stack up against PACB right now.
- NEUTRALONT.LOxford Nanopore Technologies
HOTTER — capturing the portable and low-CapEx long-read market with a more flexible pricing model than PACB's heavy Revio hardware.
See full analysis → - NEUTRALILMNIllumina, Inc.
HOTTER — despite its own regulatory woes, it maintains a dominant 80% market share and generates substantial recurring consumable revenue.
See full analysis → - COLDTXG10x Genomics
NEUTRAL — similarly hit by the biotech spending slowdown but maintains a stronger competitive moat in spatial biology and single-cell analysis.
See full analysis →
- PACB+0.0%
- ONT.L+62.8%
- ILMN+10.7%
- TXG+32.9%
Analyst price target
Consensus average of 4 analysts · median 3.00
Source: StockAnalysis.com · updated 2026-08-17
AI-generated analysis for informational purposes only. Not financial advice.